Wellington Management Group LLP Lowers Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Wellington Management Group LLP reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 22.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 88,591 shares of the specialty pharmaceutical company's stock after selling 26,049 shares during the period. Wellington Management Group LLP owned approximately 0.28% of Collegium Pharmaceutical worth $2,538,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Collegium Pharmaceutical by 11.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company's stock worth $1,902,000 after purchasing an additional 7,063 shares in the last quarter. Velan Capital Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $822,000. Vident Advisory LLC boosted its position in shares of Collegium Pharmaceutical by 27.8% during the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company's stock worth $484,000 after purchasing an additional 3,672 shares in the last quarter. Finally, Virtus Fund Advisers LLC boosted its position in shares of Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 565 shares in the last quarter.

Insider Activity at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 977 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now owns 164,269 shares of the company's stock, valued at approximately $4,928,070. The trade was a 0.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares of the company's stock, valued at $3,732,630. The trade was a 1.78% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,677 shares of company stock valued at $410,414. 2.51% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on COLL shares. Piper Sandler restated a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Trading Up 0.3%

NASDAQ:COLL opened at $29.50 on Friday. The company has a market capitalization of $947.89 million, a PE ratio of 12.72 and a beta of 0.63. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The stock has a fifty day simple moving average of $27.98 and a 200-day simple moving average of $29.59.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company's quarterly revenue was up 22.7% compared to the same quarter last year. During the same period last year, the firm earned $1.45 EPS. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.